Minimal change disease as a modifiable podocyte paracrine disorder.
作者信息
Wei Changli, Reiser Jochen
机构信息
Division of Nephrology and Hypertension, Leonard Miller School of Medicine, University of Miami, Miami, FL, USA.
出版信息
Nephrol Dial Transplant. 2011 Jun;26(6):1776-7. doi: 10.1093/ndt/gfr124. Epub 2011 Mar 17.
Abstract
摘要
相似文献
1
Minimal change disease as a modifiable podocyte paracrine disorder.
Nephrol Dial Transplant. 2011 Jun;26(6):1776-7. doi: 10.1093/ndt/gfr124. Epub 2011 Mar 17.
2
Minimal change disease following influenza vaccination and acute renal failure: just a coincidence?
Nefrologia. 2012 May 14;32(3):414-5. doi: 10.3265/Nefrologia.pre2012.Feb.11370.
3
Minimal change disease in graft versus host disease: a podocyte response to the graft?
Clin Nephrol. 2013 Dec;80(6):469-73. doi: 10.5414/CN107420.
4
Ultrastructural features and expression of cytoskeleton proteins of podocyte from patients with minimal change disease and focal segmental glomerulosclerosis.
Ren Fail. 2008;30(5):477-83. doi: 10.1080/08860220802060497.
5
[Minimal change nephrotic syndrome and Crohn disease].
Nefrologia. 2005;25(2):209-10.
6
Approach to Diagnosis and Management of Primary Glomerular Diseases Due to Podocytopathies in Adults: Core Curriculum 2020.
Am J Kidney Dis. 2020 Jun;75(6):955-964. doi: 10.1053/j.ajkd.2019.12.019. Epub 2020 Apr 21.
7
Minimal change disease: a CD80 podocytopathy?
Semin Nephrol. 2011 Jul;31(4):320-5. doi: 10.1016/j.semnephrol.2011.06.002.
8
Minimal change disease: a "two-hit" podocyte immune disorder?
Pediatr Nephrol. 2011 Apr;26(4):645-9. doi: 10.1007/s00467-010-1676-x. Epub 2010 Oct 30.
9
Secondary minimal change disease.
Nephrol Dial Transplant. 2003 Aug;18 Suppl 6:vi52-8. doi: 10.1093/ndt/gfg1060.
10
Podocyte autophagy is associated with foot process effacement and proteinuria in patients with minimal change nephrotic syndrome.
PLoS One. 2020 Jan 24;15(1):e0228337. doi: 10.1371/journal.pone.0228337. eCollection 2020.
引用本文的文献
1
Sulfatase 2 Is Associated with Steroid Resistance in Childhood Nephrotic Syndrome.
J Clin Med. 2021 Feb 2;10(3):523. doi: 10.3390/jcm10030523.
2
Tacrolimus Monotherapy after Intravenous Methylprednisolone in Adults with Minimal Change Nephrotic Syndrome.
J Am Soc Nephrol. 2017 Apr;28(4):1286-1295. doi: 10.1681/ASN.2016030342. Epub 2016 Nov 2.
3
Protective effects of low-dose rapamycin combined with valsartan on podocytes of diabetic rats.
Int J Clin Exp Med. 2015 Aug 15;8(8):13275-81. eCollection 2015.
4
Proteinuria predicts relapse in adolescent and adult minimal change disease.
Clinics (Sao Paulo). 2012 Nov;67(11):1271-4. doi: 10.6061/clinics/2012(11)08.
5
The glomerular filtration barrier: components and crosstalk.
Int J Nephrol. 2012;2012:749010. doi: 10.1155/2012/749010. Epub 2012 Aug 14.
6
Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.
Int Urol Nephrol. 2013 Jun;45(3):795-802. doi: 10.1007/s11255-012-0206-0. Epub 2012 Jul 15.
7
Childhood nephrotic syndrome--current and future therapies.
Nat Rev Nephrol. 2012 Jun 12;8(8):445-58. doi: 10.1038/nrneph.2012.115.
8
Angiotensin II induces nephrin dephosphorylation and podocyte injury: role of caveolin-1.
Cell Signal. 2012 Feb;24(2):443-450. doi: 10.1016/j.cellsig.2011.09.022. Epub 2011 Oct 1.
本文引用的文献
1
Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome.
Nat Med. 2011 Jan;17(1):117-22. doi: 10.1038/nm.2261. Epub 2010 Dec 12.
2
Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.
Clin J Am Soc Nephrol. 2010 Nov;5(11):2115-21. doi: 10.2215/CJN.03800609. Epub 2010 Oct 21.
3
Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling.
J Am Soc Nephrol. 2010 Oct;21(10):1691-701. doi: 10.1681/ASN.2010030295. Epub 2010 Aug 5.
4
Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.
Kidney Int. 2010 Aug;78(3):296-302. doi: 10.1038/ki.2010.143. Epub 2010 May 19.
5
Proteinuria: an enzymatic disease of the podocyte?
Kidney Int. 2010 Apr;77(7):571-80. doi: 10.1038/ki.2009.424. Epub 2009 Nov 18.
6
Impacts of angiopoietin-like proteins on lipoprotein metabolism and cardiovascular events.
Curr Opin Lipidol. 2010 Feb;21(1):70-5. doi: 10.1097/MOL.0b013e328333269e.
7
New insights into the role of podocytes in proteinuria.
Nat Rev Nephrol. 2009 Aug;5(8):463-8. doi: 10.1038/nrneph.2009.108. Epub 2009 Jul 7.
8
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4.
Cell. 2008 Apr 4;133(1):66-77. doi: 10.1016/j.cell.2008.01.046.
9
The role of angiopoietin-like proteins in angiogenesis and metabolism.
Trends Cardiovasc Med. 2008 Jan;18(1):6-14. doi: 10.1016/j.tcm.2007.10.003.
10
Minimal change nephropathy and focal segmental glomerulosclerosis.
Semin Immunopathol. 2007 Nov;29(4):415-26. doi: 10.1007/s00281-007-0094-z. Epub 2007 Oct 23.
Zotero 插件